This is a preview of subscription content, log in via an institution to check access.
Notes
2015 New Zealand dollars
pneumococcal conjugate vaccines
Reference
Varghese L, et al. A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand. Applied Health Economics and Health Policy : 9 Apr 2018. Available from: URL: http://doi.org/10.1007/s40258-018-0387-5
Rights and permissions
About this article
Cite this article
Synflorix cost saving compared with Prevenar in New Zealand. PharmacoEcon Outcomes News 801, 33 (2018). https://doi.org/10.1007/s40274-018-4888-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-4888-0